Advertisement
Screener

VERU INC. (VERU) Treasury Stock, Value, Acquired, Cost Method

2.8 / 5 stars · 68/120 Roast Me

VERU INC. Treasury Stock, Value, Acquired, Cost Method

Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).

  • VERU INC. treasury stock, value, acquired, cost method for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
  • VERU INC. treasury stock, value, acquired, cost method for the quarter ending 2015-12-31 was $0.00.
  • VERU INC. treasury stock, value, acquired, cost method for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
  • VERU INC. treasury stock, value, acquired, cost method for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
  • VERU INC. treasury stock, value, acquired, cost method for fiscal 2015 was $950.00, a 99.87% decline from fiscal 2014.
  • VERU INC. treasury stock, value, acquired, cost method for fiscal 2014 was $737.75K, a 86.46% increase from fiscal 2013.
  • VERU INC. treasury stock, value, acquired, cost method for fiscal 2013 was $395.67K, a 36.62% increase from fiscal 2012.
  • VERU INC. treasury stock, value, acquired, cost method for fiscal 2012 was $289.61K.
Period endTreasury Stock, Value, Acquired, Cost Method 3 monthTreasury Stock, Value, Acquired, Cost Method 12 month
2016-03-31$0.00
derived: 10-Q 111 month − 10-Q 108 month · filed 2016-04-28
$0.00
derived: sum of 4 quarters · filed 2018-01-02
2015-12-31$0.00
derived: 10-Q 108 month − 10-Q 105 month · filed 2016-02-02
$950.00
derived: sum of 4 quarters · filed 2018-01-02
2015-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-02
$950.00
10-K · filed 2018-01-02
2015-06-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-07-30
$520.86K
derived: sum of 4 quarters · filed 2016-12-12
2015-03-31$950.00
10-Q · filed 2015-07-30
$728.33K
derived: sum of 4 quarters · filed 2016-12-12
2014-12-31$0.00
derived: 10-Q 96 month − 10-Q 93 month · filed 2015-02-03
$737.75K
derived: sum of 4 quarters · filed 2016-12-12
2014-09-30$519.91K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-12
$737.75K
10-K · filed 2016-12-12
2014-06-30$207.47K
10-Q · filed 2014-07-31
2014-03-31$10.37K
10-Q · filed 2014-07-31
2013-12-31$0.00
derived: 10-Q 84 month − 10-Q 81 month · filed 2014-02-03
2013-09-30$395.67K
10-K · filed 2015-12-02
2012-09-30$289.61K
10-K · filed 2014-12-02
2011-09-30-$33.06K
10-K · filed 2013-12-03
2010-09-30-$349.06K
10-K · filed 2012-12-04
2009-09-30-$3.83M
10-K · filed 2011-12-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kairos Pharma, LTD. (KAPA)United States$0.041B
SCYNEXIS INC (SCYX)United States$0.045B
PDS Biotechnology Corp (PDSB)United States$0.045B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
CervoMed Inc. (CRVO)United States$0.038B-1.39
Celularity Inc (CELU)United States$0.038B-0.34